Table 1.
Baseline Characteristics of the Mupirocin vs. Placebo Group
| Mupirocin (n=46) | Placebo (n=46) | P value | |
|---|---|---|---|
| Characteristic | N (%) | N (%) | |
| S. aureus nasal colonization | 20 (43) | 22 (48) | 0.68 |
| Previous S. aureus infection ^ | 8 (17) | 4 (9) | 0.36 |
| Demographics | |||
| Gender: | |||
| Male | 38 (83) | 37 (80) | 0.79 |
| Female | 8 (17) | 9 (20) | |
| Age (mean ±SD) | 43.0 ± 6.7 | 42.7 ± 7.5 | 0.84 |
| Race: | 0.25 | ||
| Black--not hispanic | 33 (72) | 26 (57) | |
| Hispanic | 8 (17) | 15 (33) | |
| White | 4 (9) | 5 (11) | |
| No Response | 1 (2) | 0 (0) | |
| Education: | 0.97 | ||
| < High school | 22 (48) | 21 (46) | |
| Completed high school | 12 (26) | 13 (28) | |
| > High school | 12 (26) | 12 (26) | |
| Medical History (baseline) | |||
| AIDS diagnosis | 46 (100) | 40 (87) | 0.0113 |
| Years since tested HIV-positive (mean ±SD) | 12.5 ± 5.2 | 9.8 ± 5.4 | 0.0152 |
| CD4 count | 0.30 | ||
| <200 | 23 (50) | 30 (65) | |
| 201–350 | 12 (26) | 7 (15) | |
| >350 | 11 (24) | 9 (20) | |
| HIV viral load | 0.93 | ||
| undetectable* | 11 (24) | 13 (28) | |
| 50–1000 | 11 (24) | 9 (20) | |
| 1001–50000 | 14 (30) | 13 (28) | |
| >50000 | 10 (22) | 11 (24) | |
| Receiving HAART | 25 (54) | 25 (54) | 1.00 |
| Viral hepatitis | 24 (52) | 25 (54) | 0.83 |
| Diabetes | 1 (2) | 5 (11) | 0.09 |
^
Infection at or within one month prior to randomization
*
undetectable defined as VL <50 or <400 depending on year